5-Azacitidine + PD-1/PD-L1 Inhibitors for Cancer

This trial aims to determine the optimal dose of 5-Azacitidine when combined with PD-1/PD-L1 inhibitors for treating certain stubborn cancers. These cancers did not respond to PD-1/PD-L1 treatments, which are immunotherapies designed to help the immune system fight cancer. The trial uses 5-Azacitidine, a type of chemotherapy, alongside one of three approved PD-1/PD-L1 inhibitors: Pembrolizumab, Nivolumab, or Cemiplimab. It may suit individuals with advanced cancers that have not responded to PD-1 or PD-L1 treatments and have experienced tumor growth despite previous treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using systemic steroids or have taken chemotherapy, immunosuppressive agents, or investigational drugs within 28 days before starting the study.

Research has shown that combining 5-Azacitidine with PD-1/PD-L1 inhibitors has produced mixed safety results in past studies. In some cases, serious side effects, including deaths, occurred during treatment with azacitidine and nivolumab. These were specific cases and do not represent all outcomes.

In studies involving azacitidine and pembrolizumab, treatments were generally well-tolerated, though some side effects occurred. These side effects, common in cancer treatments, might include fatigue or nausea.

PD-1/PD-L1 inhibitors, such as pembrolizumab, nivolumab, and cemiplimab, have already received FDA approval for other uses. This approval indicates their safety is well-known and generally considered acceptable, though individual reactions can vary.

Most treatments for cancer focus on directly attacking cancer cells or boosting the immune system to fight the cancer. However, the unique combination of 5-Azacitidine with PD-1/PD-L1 inhibitors like Pembrolizumab, Nivolumab, or Cemiplimab offers a novel approach. 5-Azacitidine works by modifying DNA in cancer cells, making them more recognizable to the immune system. When combined with PD-1/PD-L1 inhibitors, which prevent cancer cells from hiding from immune attacks, the treatment could potentially enhance the body's ability to identify and destroy cancer cells more effectively. Researchers are excited about this combination because it represents a two-pronged strategy: altering cancer cells for better immune detection and enhancing immune response, which could lead to improved outcomes for patients.

This trial will assess the combination of 5-Azacitidine with PD-1/PD-L1 inhibitors, including Pembrolizumab, Nivolumab, and Cemiplimab. Research has shown that combining 5-Azacitidine with these inhibitors might improve cancer treatment. Specifically, some studies have shown that using Azacitidine with Nivolumab holds promise in treating certain blood cancers, making the treatment safer and more effective. These inhibitors help the immune system attack cancer cells, and 5-Azacitidine may enhance their effectiveness by affecting cancer cell growth. Early results are encouraging, but more research is needed to determine if these benefits apply to other cancer types.⁵⁶⁷⁸⁹